Previous studies have reported that eEF-2K knockdown sensitizes glioma cells to TRAIL [23], 2-deoxy-D-glucose [20] and the Akt inhibitor MK-2206 [21], as well as breast cancer cells to the inhibition of growth factor receptor signaling [24]. This evidence concerns the gene EEF2K and central nervous system cancer.